Thrivent Financial for Lutherans Purchases 58,451 Shares of Avanos Medical, Inc. $AVNS

Thrivent Financial for Lutherans lifted its position in Avanos Medical, Inc. (NYSE:AVNS) by 38.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 212,215 shares of the company’s stock after acquiring an additional 58,451 shares during the period. Thrivent Financial for Lutherans’ holdings in Avanos Medical were worth $2,383,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Russell Investments Group Ltd. raised its position in shares of Avanos Medical by 969.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock worth $31,000 after acquiring an additional 2,307 shares in the last quarter. Wexford Capital LP bought a new position in shares of Avanos Medical in the 3rd quarter worth approximately $70,000. Tower Research Capital LLC TRC raised its position in shares of Avanos Medical by 433.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company’s stock worth $77,000 after acquiring an additional 5,083 shares in the last quarter. Quantessence Capital LLC bought a new position in shares of Avanos Medical in the 3rd quarter worth approximately $116,000. Finally, Virtu Financial LLC bought a new position in shares of Avanos Medical in the 3rd quarter worth approximately $136,000. Institutional investors own 95.17% of the company’s stock.

Avanos Medical Stock Performance

Avanos Medical stock opened at $24.65 on Tuesday. The company has a quick ratio of 1.40, a current ratio of 2.48 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $1.15 billion, a P/E ratio of -15.31 and a beta of 1.58. The stock’s 50 day moving average is $19.89 and its 200 day moving average is $15.13. Avanos Medical, Inc. has a twelve month low of $9.30 and a twelve month high of $24.91.

Avanos Medical (NYSE:AVNS) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $0.22 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.06. The company had revenue of $182.20 million for the quarter, compared to the consensus estimate of $170.00 million. Avanos Medical had a positive return on equity of 5.39% and a negative net margin of 10.39%.The firm’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.26 EPS. On average, equities research analysts predict that Avanos Medical, Inc. will post 1.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on AVNS shares. Weiss Ratings upgraded Avanos Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 22nd. Zacks Research downgraded Avanos Medical from a “hold” rating to a “strong sell” rating in a research note on Thursday, May 7th. Finally, Wall Street Zen downgraded Avanos Medical from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. Two analysts have rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Avanos Medical Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.